Corrupt practices cost healthcare $23 billion
Fraud and abuse in healthcare costs individual governments as much as $23 billion a year, according to estimates from the World Health Organization (WHO). More...
M&As to push 2014 sales to $381 billion
M&As remain an integral part of Big Pharma's strategy and will contribute almost two-thirds of peer set sales growth up to 2014, according to market analysts firm Datamonitor. More...
FDA recommended to continue work on postmarket safety issues
The Government Accountability Organization (GAO) has recommended that the FDA Commissioner develop a comprehensive plan for transferring additional regulatory authorities from the Office of New Drugs (OND) to the Office of Surveillance and Epidemiology (OSE) to help address weaknesses in the agency’s oversight of postmarket drug safety. More...
EPHA proposes improvements to medicines directive
The European Public Health Alliance (EPHA) has published its comments about the Falsified Medicines Directive, which is currently under debate by the European Parliament and Council. More...
Pharma must improve sustainability reporting
Analysis examining voluntary environmental and social reporting for 26 of the world's largest pharmaceutical companies has revealed that many big players, including Pfizer, have room for improvement. More...
Join PTE on LinkedIn!
Join Pharmaceutical Technology Europe's group on LinkedIn. More...
Eli Lilly plans 2 drug launches per year from 2013
Eli Lilly has outlined its growth strategy at its annual meeting with the investment community; chief among the company’s goals are plans to launch two new drugs per year beginning in 2013 and a strategy to increase its position in emerging markets. More...
Are you following us?
Pharmaceutical Technology Europe is on Twitter. More...
| On Demand Webcast |
| Just Systems |
|
Complex Documents in the Pharmaceutical Industry Made Easy
Documents are created just about everywhere in the pharmaceutical industry. To manage interrelated documents, collaboratively created and updated, versioned and published to different targets can often turn into a nightmare. With XML authoring, recurrent tasks such as applying repetitive changes to similar documents or assuring quality for cross-referencing, can finally be automated.
 Read more... |
|
|
|
|
| Podcast |
| Vetter Development Service Chicago |
|
Peter Soelkner
Managing Director,
Vetter Pharma International GmbH
Listen to this podcast recorded live from the show floor of AAPS 2009. Clinical development is key for new drugs. In order to minimize risks and take advantage of opportunities, you need comprehensive know-how and years of experience. Vetter, as a specialist in the aseptic filling of injection systems, will provide with its new facility the manufacturing of preclinical, Phase I and Phase II clinical batches in Chicago. We invite you to find out more about
 Vetter Development Service Chicago.
|
|
|
|
|
|
|
| |
| |
| Latest peer-reviewed research |
|
|
|
